MTARC1 and metabolic dysfunction-associated steatohepatitis: The current study is the first to demonstrate that loss of mARC1 in vivo, by both genetic KO or siRNA-mediated knockdown, results in protection from disease progression in 4 distinct models of MASH and liver fibrosis and that the timing of intervention is critical to observe a protective phenotype.